Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery
NCT00331760
Completed
RATIONALE: Specialized radiation therapy (RT), such as intensity-modulated radiation therapy (IMRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving intensity-modulated radiation therapy to the pelvis with or without chemotherapy after surgery ma... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/01/2019
Locations: Auburn Radiation Oncology, Auburn, California +152 locations
Conditions: Cervical Cancer, Endometrial Cancer
Register for Updates
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
NCT02433626
Unknown
Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head and neck squamous cell carcinoma (HNSCC) as well as a variety of other tumor types. This study is designed primarily to assess the safety and tolerability of COTI-2 monotherapy or combination therapy in patients with advanced and recurrent malignancies to establish a r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2019
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer, Peritoneal Cancer, Head and Neck Cancer, HNSCC, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Register for Updates
CHFR Methylation Status Esophageal Cancer Study
NCT01372202
Terminated
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/23/2019
Locations: Ronan Kelly, M.D., Baltimore, Maryland
Conditions: Esophageal Cancer
Register for Updates
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery
NCT00281970
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving docetaxel together with cisplatin works in treating patients with stage I, stage II, or stage III non-small cell lung cancer that has been completely removed... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/15/2019
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland +2 locations
Conditions: Lung Cancer
Register for Updates
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
NCT00882583
Terminated
Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2. To determine the MTD of daily oral dasatinib in combination with cisplatin/cetuximab/RT in Cohort B
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/08/2019
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
NCT00231842
Completed
The optimal sequence and /or modality for adjuvant therapy in the management of Mixed Mesodermal Tumors (MMT) clearly remains to be established. The rationale for the protocol is to "sandwich" pelvic radiation with chemotherapy to decrease distant metastasis. The proposed study will sandwich radiation between the two most active chemotherapeutic agents for MMT identified to date (ifosfamide/cisplatin). By doing so, we attempt to decrease both local and distant recurrence, which may translate in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2019
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Uterine Cancer
Register for Updates
A Safety Study in Participants With Advanced Solid Tumors
NCT01284335
Terminated
The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associated with the LY573636 combination treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2018
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +18 locations
Conditions: Advanced Solid Tumors
Register for Updates
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
NCT00924209
Terminated
Background: * Surgical resection is the treatment of choice for patients with lung cancer, and cure after resection generally depends on whether lymph nodes are involved. A patient with Stage IIIA (N2) lung cancer has cancer in the lymph nodes involving the center of the chest (mediastinum). * Studies have shown that surgery alone as a treatment for Stage IIIA (N2) lung cancer is not as effective as chemotherapy followed by surgery. * Giving chemotherapy upfront may prevent the spread of Stage... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
11/29/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland +1 locations
Conditions: NSCLC, Stage IIIA (N2)
Register for Updates
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
NCT00084318
Completed
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cisplatin and docetaxel may make the tumor cells more sensitive to radiation therapy. Combining a monoclonal antibody w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2018
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +159 locations
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Lymphoma
NCT00002835
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
Gender:
ALL
Ages:
Between 15 years and 59 years
Trial Updated:
11/13/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
NCT00002565
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodg... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
11/13/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas +2 locations
Conditions: Lymphoma
Register for Updates
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
NCT00493025
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving gefi... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/12/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Esophageal Cancer
Register for Updates